Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Peregrine Pharmaceuticals
With that in mind, let's take a closer look at Peregrine's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Tustin, Calif. (1981)|
|Market Cap||$298.0 million|
|Trailing-12-Month Revenue||$15.2 million|
|Management||CEO Steven King (since 2003)
CFO Paul Lytle (since 2002)
|Return on Equity (average, past 3 years)||(259.3%)|
|Cash/Debt||$18 million / $124 thousand|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 74% of the 35 All-Star members who have rated Peregrine believe the stock will underperform the S&P 500 going forward.
They're now a four-bagger and counting from the June low of [$0.43]. ... Now, of course, the upward momentum is pure speculation in the usual game of baby biotech chicken.
Red flag one is that [bavituximab] has been around for like, forever. Longer than I've been following biotech. That's a long time for a miracle drug to reveal its miraculous nature.
Red flag two is that [progression free survival] was only 4.5 months vs 3 months for standard of care. Better than nothing, but not necessarily predictive of prolonged survival. ...
Red flag three is that the company released very little of the data from the trial. Statistical significance?
Red flag four is that the share price didn't start taking off until a month after the data release in May. ... The delayed reaction reeks of manipulation and speculation.
Red flag five is courtesy of Adam Feuerstein, who points out that Peregrine has made a business model out of selling stock through unannounced ATM financings for years. ...
If you don't want to miss that kind of dilution and you can't bring yourself to pore through the quarterly SEC filings, just remember to click that cash flow link under Financials on Yahoo Finance. They can dilute without telling you in PR, but they can't hide their Sale Purchase of Stock.
If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
More from The Motley Fool
3 Drug Stocks That Soared This Week: Are They Buys?
Can Catalyst, Sucampo, and Peregrine keep the momentum going?
It's the Little Things That Matter for Peregrine Pharmaceuticals
Peregrine Pharmaceuticals' shares rose 15% in November, and two subtle press releases provided the spark.
Peregrine Pharmaceuticals' Stock Sank in September: Is It Now a Buy?
Peregrine Pharmaceuticals' stock had a rough September. Should investors take advantage of this pullback to add this speculative biopharma to their portfolios?